



FOR IMMEDIATE RELEASE

Media Contact

Ian Stone

Russo Partners

Tel: +1 619 528 2220

ian.stone@russopartnersllc.com

Alder Biopharmaceuticals to Present at Piper Jaffray & Co. 21st Annual Healthcare Conference

BOTHELL, Wash., November 30, 2009 – Alder Biopharmaceuticals, Inc., announced today that Randall Schatzman, Ph.D., president and chief executive officer, will present a company overview at the Piper Jaffray & Co. 21st Annual Healthcare Conference. The presentation is scheduled for 8:30 a.m. EST on Wednesday, December 2, at The Pierre Hotel in New York City.

“This is an exciting time at Alder as we continue to grow our pipeline by applying our core technologies to rapidly discover and develop monoclonal antibody therapeutic candidates,” Schatzman said. “We look forward to updating the investment community on our next steps following the successful initiation of our partnership with Bristol-Myers Squibb for ALD518.”

About Alder

Alder Biopharmaceuticals, Inc. uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. In addition to Bristol-Myers Squibb, partners include Schering-Plough, Seattle Genetics, Genmab, and two non-disclosed large pharmaceutical companies. For more information, visit www.alderbio.com.